Schizophrenia
Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.
CompletedNCT05053451
Official study titleTranscranial Direct Current Stimulation (tDCS) Studies of Auditory Hallucinations, Negative Symptoms and Cognition in Schizophrenia
This study has finished and is no longer accepting participants.
In SacramentoSchizophreniaDevice studyAges 18–65
- Countries
- United States
- Sponsor
- University of California, Davis
CompletedNCT02911519
Official study titleEfficacy of a Brief Group Psychoeducation Program Aimed at Patients With Schizophrenia and Their Families: A Clinical Controlled Trial
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaInterventional studyAges 18–65
- Countries
- Sponsor
- Salud Mental Integral S.A.S.
CompletedNCT02538445
This study has finished and is no longer accepting participants.
In Saint-EtienneSchizophreniaInterventional studyAges 18–50
- Countries
- France
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
CompletedNCT00821600
Official study titleSingle-Dose, Open-Label Pilot Study to Explore the Pharmacokinetics, Safety and Tolerability of a Gluteal Intramuscular Injection of a 4-Week Long-Acting Injectable Formulation of Risperidone in Patients With Chronic Stable Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including CerritosSchizophreniaMedication studyAges 18–55
- Countries
- United States
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
CompletedNCT01164059
About this title
Clinical Effectiveness of Newer Antipsychotics in Comparison With Conventional Antipsychotics in Schizophrenia
Read the official source — NCT01164059What is this study about?This study evaluated the effectiveness of Olanzapine for people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including AachenSchizophreniaMedication studyAges 18–65
- Countries
- Germany
- Sponsor
- University of Bremen
CompletedNCT02832037
Official study titleA Phase II Randomised, Double-blinded, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of 4 Oral Doses of BI 425809 Once Daily Over 12 Week Treatment Period in Patients With Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including Garden GroveSchizophreniaMedication studyAges 18–50
- Countries
- United States, Canada, United Kingdom, + 8 others
- Sponsor
- Boehringer Ingelheim
TerminatedNCT00044083
Official study titleRandomized, Double-Blinded, Placebo Controlled Study of the Effects of Tolcapone and Entacapone on Cognitive Function in Patients With Schizophrenia and Normal Controls Based on COMT Genotype
This study ended early.
In BethesdaSchizophreniaMedication studyAges 18–50
- Countries
- United States
- Sponsor
- National Institute of Mental Health (NIMH) (Government agency)
WithdrawnNCT01448499
Official study titleClozapine Versus Amisulpride Versus Their Combination in the Treatment of Drug-resistant Schizophrenia Patients
This study was withdrawn before enrollment.
In Petah TikvaSchizophreniaMedication studyAges 18–65
- Countries
- Israel
- Sponsor
- Geha Mental Health Center
TerminatedNCT00169039
Official study titleClozapine Response and Biogenic Amines in Schizophrenia
This study ended early.
In Jamaica PlainSchizophreniaMedication studyAges 19–60
- Countries
- United States
- Sponsor
- Harvard Medical School (HMS and HSDM)
TerminatedNCT00169091
Official study titleClozapine or Haloperidol in First Episode Schizophrenia
This study ended early.
In Jamaica PlainSchizophreniaMedication studyAges 18–45
- Countries
- United States
- Sponsor
- Harvard Medical School (HMS and HSDM)
CompletedNCT02874482
Official study titleStudy of Cognitive and Emotional Factors Influencing the Visual Exploration Among Patients With Schizophrenia
This study has finished and is no longer accepting participants.
In LilleSchizophreniaObservational studyAges 18+
- Countries
- France
- Sponsor
- University Hospital, Lille
CompletedNCT07609953
Official study titleEffectiveness of Cognitive Behavioral Therapy as Adjunctive Therapy on Cognitive Function and Serum Brain-Derived Neurotrophic Factor Levels in Patients With Schizophrenia Receiving Risperidone Therapy
This study has finished and is no longer accepting participants.
In MakassarSchizophreniaMedication studyAges 20–50
- Countries
- Indonesia
- Sponsor
- Hasanuddin University